Efficacy and Safety of Atezolizumab Plus Bevacizumab for Patients With Hepatocellular Carcinoma and Child–Pugh Class B
Liver International · 2026
DOI: 10.1111/liv.70466 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Liver International, 2026. Verfasst von Ryu Sasaki und 25 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Bevacizumab, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background & Aims Despite the advances in systemic therapy for unresectable hepatocellular carcinoma (HCC), patients with Child–Pugh class B (CP‐B) liver function face a significant unmet need. This study evaluated the efficacy and safety of atezolizumab plus bevacizumab (Atez/Bev) in patients with unresectable HCC and CP‐B.
Methods
This retrospective study included 796 patients who received Atez/Bev between October 2020 and July 2024 from 10 institutions in Japan. The median observation period was 14.6 months. The liver function was assessed using the CP classification and modified ALBI (mALBI) grade. The progression‐free survival (PFS), overall survival (OS) and median survival time (MST) were evaluated.
Results
Patients with CP‐B had significantly shorter PFS and OS than those with CP‐A (median PFS, 4.6 months vs. 7.0 months; MST, 10.3 months vs. 23.2 months) (PFS, p = 0.009; OS, p < 0.001). Although CP‐B was associated with a higher incidence of bleeding‐related events, the discontinuation rate due to adverse events did not differ from that of CP‐A. As a factor for stratifying CP‐B outcomes, significant differences in the PFS, OS and response rate were observed between mALBI grades ≤ 2b and 3 (PFS, p = 0.004; OS, p = 0.024; response rate, p = 0.001). In multivariate analysis, the mALBI grade (hazard ratio [95% CI]: 2.388 [1.186–4.810]; p = 0.014) was extracted as a factor contributing to OS in patients with CP‐B.
Conclusion
Atez/Bev therapy demonstrated efficacy and safety in patients with CP‐B, especially when hepatic reserve is maintained within mALBI grade 2b.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
- Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan.
- Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan.
- Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
- Department of Gastroenterology, Okayama University Hospital, Okayama, Japan.
- Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Takamatsu, Kagawa, Japan.
ORCID-Profile: Ryu Sasaki, Shigeo Shimose, Issei Saeki, Yasuto Takeuchi, Tetsu Tomonari, Satoru Kakizaki, Takeshi Hatanaka, Satoshi Miuma, Hideki Iwamoto, Norikazu Tanabe, Takafumi Yamamoto, Atsushi Naganuma, Sohji Nishina, Tetsuji Takayama, Motoyuki Otsuka, Taro Takami, Takumi Kawaguchi, Hisamitsu Miyaaki
Zitieren
APA
Sasaki, R., Shimose, S., Saeki, I., Ito, T., Takeuchi, Y., Tani, J., Tomonari, T., Sasaki, K., Kakizaki, S., Hatanaka, T., Miuma, S., Shirono, T., Iwamoto, H., Tanabe, N., Yamamoto, T., Kanayama, Y., Naganuma, A., Nishina, S., Takayama, T., …, & Hepatology InVestigator Experts in Japan (HIVE‐J) Study Group (2026). Efficacy and Safety of Atezolizumab Plus Bevacizumab for Patients With Hepatocellular Carcinoma and Child–Pugh Class B. Liver International. https://doi.org/10.1111/liv.70466
Vancouver
Sasaki R, Shimose S, Saeki I, Ito T, Takeuchi Y, Tani J, et al. Efficacy and Safety of Atezolizumab Plus Bevacizumab for Patients With Hepatocellular Carcinoma and Child–Pugh Class B. Liver International. 2026. doi:10.1111/liv.70466
BibTeX
@article{Sasaki2026,
author = {Sasaki, Ryu and Shimose, Shigeo and Saeki, Issei and Ito, Takanori and Takeuchi, Yasuto and Tani, Joji and Tomonari, Tetsu and Sasaki, Kyo and Kakizaki, Satoru and Hatanaka, Takeshi and Miuma, Satoshi and Shirono, Tomotake and Iwamoto, Hideki and Tanabe, Norikazu and Yamamoto, Takafumi and Kanayama, Yuki and Naganuma, Atsushi and Nishina, Sohji and Takayama, Tetsuji and Kobara, Hideki and Otsuka, Motoyuki and Kawashima, Hiroki and Takami, Taro and Kawaguchi, Takumi and Miyaaki, Hisamitsu and Hepatology InVestigator Experts in Japan (HIVE‐J) Study Group, Hepatology InVestigator Experts in Japan (HIVE‐J) Study Group},
title = {Efficacy and Safety of Atezolizumab Plus Bevacizumab for Patients With Hepatocellular Carcinoma and Child–Pugh Class B},
journal = {Liver International},
year = {2026},
doi = {10.1111/liv.70466}
}
EUVIMED